U.S. Uterine Fibroid Treatment MarketChallenges and Opportunities

U.S. Uterine Fibroid Treatment Market, By Procedure Type (Endometrial Ablation, MRI Guided Procedures (MRI-guided Percutaneous Laser Ablation, and MRI-guided Transcutaneous Focused Ultrasound), Hysterectomy (Abdominal Hysterectomy, Vaginal Hysterectomy, Laparoscopic Hysterectomy, Robotic Hysterectomy, and Hysteroscopic Morcellation), Myomectomy (Open Myomectomy, Laparoscopic Myomectomy, and Robotic Myomectomy), Uterine Artery Embolization, Radiofrequency Ablation, and Others) and By End User (Hospitals and Ambulatory Surgical Centers)-

Published In : Jun 2023

Code : CMI3866

Pages :166

Formats :

Excel and PDF

Industry : Medical Devices

Market Challenges And Opportunities

U.S Uterine Fibroids Treatment Market– Drivers

High incidence of uterine fibroids among women

Increasing incidence of uterine fibroids among women is expected to boost growth of the U.S uterine fibroids treatment market over the forecast period. For instance, on May 13 2023, according to an article published in the Journal of Biomed Central Women's Health, the prevalence of UL (Uterine leiomyomata (Fibroids)) was approximately 12.92% in U.S. in 2020, and is estimated to increase up to 80 % by 2025.

Rising number of hysterectomy

The rising number of hysterectomy surgical procedures is one of the main drivers of market growth. Furthermore, this method is the most popular and well-proven permanent treatment for uterine fibroids. As a result, the hysterectomy will likely grow as the number of related surgeries increases. For instance, in November 2020, according to an article published in the Journal of Gynecologic Oncology, according to the Centers for Disease Control and Prevention (CDC), about 600,000 hysterectomies are performed in the United State each year. For instance in November 2022, according to the American College of Obstetricians and Gynecologists, around a third of all women will have a hysterectomy by age 60.

U.S Uterine Fibroids Treatment Market: Restraint

Complications associated with the morcellators

Complications associated with morcellators are expected to hinder growth of the U.S. uterine fibroids treatment market. Laparoscopic power morcellators are used in hysterectomy and myomectomy procedures for the treatment of uterine fibroids. However, power morcellators could cause complications such as metastatic leiomyosarcoma cancer. So, avoiding the use of morcellators, and the use of other laparoscopic techniques to be followed for uterine fibroid removal. For instance, in November 2022, according to an article published by the Drugwatch, surgery with a morcellator has higher risks such as Intra-abdominal abscesses, Organ damage, Bleeding or infection and many others. Even non-cancerous fibroid tissue may be spread by a morcellator. Non-cancerous fibroid tissue can attach to other tissues and organs in the abdominal cavity, causing more fibroids to grow.